
Ketamine exerts rapid antidepressant effects in treatment-resistant depression (TRD) but therapeutic predictors remain elusive. The personality trait absorption – tendencies for immersive sensory, imaginative, and emotional experiences – influences responses to serotonergic psychedelics, like psilocybin, but has not been studied for ketamine. This study explores trait absorption’s influences on ketamine-therapy for TRD, including interactions with music- versus mindfulness-based support. This exploratory analysis draws on the MUSIK trial (NCT04701866), a multi-site, parallel, single-blind RCT at two Montreal hospitals, whose primary outcome examined hemodynamic effects of pairing ketamine with music. Thirty-two adults (aged 18-75 years) with severe TRD, receiving a structured psychedelic ketamine-therapy intervention, were randomized 1:1 to receive either music (n = 15) or matched non-music support (n = 17) during their six infusions (0.5 mg/kg over 40 min) over four weeks. Outcome assessors but not participants were blinded. Across 181 infusions, this exploratory outcome examined associations between baseline absorption and (1) changes in depression, anxiety, and suicidality; and (2) mystical/emotional experiences using linear correlations and multilevel models. Baseline trait absorption is associated (p ≤ .002) with pre-post improvements in depression (r = .721), anxiety (r = .546), and mean/peak Mystical Experience Questionnaire scores (r = .528-.637). In multilevel models, higher absorption is associated with steeper declines in depression and suicidality. Three-way interactions with timepoint and group suggest that music, versus matched non-music support, is associated with greater depression improvements in higher-absorption individuals (p <.001). Although confirmation in larger studies is required, this exploratory study suggests that trait absorption relates to ketamine’s benefits for TRD. Observed drug-context interactions highlight possible strategies for individuallytailoring ketamine-therapy. Low-dose ketamine can be very beneficial for severe depression even when other treatments have not helped. However, much remains unknown about how ketamine works and who might most benefit. This study explored how a personality trait called absorption may influence the benefits of a series of ketamine doses, paired with either music- or mindfulness-based support, for adults with severe depression. Trait absorption reflects an individual’s tendencies to become deeply immersed in sensory, imaginative, and emotional experiences. The results suggest that higher trait absorption is associated with greater benefits from ketamine, especially when administered with music. This may be because high-absorption individuals tend to have more significant ketamine experiences – indeed, the study found that higher trait absorption was associated with more mystical-like ketamine experiences. If confirmed, these results may help guide patient selection and the personalized use of mindfulness or music in ketamine therapy for depression. Garel et al. explore the influence of the personality trait absorption in the MUSIK trial which administered 181 doses of ketamine, with either music or mindfulness, for treatment-resistant depression. Higher absorption is associated with larger antidepressant effects, reduced suicidality, and more mystical experiences, especially with music-based support.
Infections are among the main complications in patients with acute myeloid leukemia (AML) undergoing intensive chemotherapy, increasing morbidity and mortality. However, no established tools exist to detect early signs of infection. Here, we develop and validate a machine learning model to predict the daily risk of febrile neutropenia (FN). We conducted a retrospective observational study using registry data from two university hospital districts in Finland. We included adult patients with newly diagnosed AML undergoing intensive chemotherapy (n = 271, 48-hour FN outcomes=540), excluding acute promyelocytic leukemia. The model used a 48-hour prediction window and 1.2 M clinical data points to generate daily FN risk estimates. We built the model using the Extreme Gradient Boosting algorithm, explained variable importance with Shapley Additive Explanations, and evaluated and validated performance using measures of discrimination, calibration, and clinical utility. We show how seven variables predict daily FN risk: white blood cell count, temperature, time since cycle start, C-reactive protein trend, absolute neutrophil count, treatment phase, and prior antibiotic treatment. We achieve an AUROC of 0.91 (95% CI, 0.89–0.93) and a calibration slope of 0.95 (95% CI, 0.73–1.16) in the development cohort’s test set (n = 55, 48-hour FN outcomes=109) and validate performance in the external cohort (n = 136, 48-hour FN outcomes=124, AUROC 0.79 (95% CI, 0.75–0.82), calibration slope 0.65 (95% CI, 0.51–0.79)). While prospective validation is warranted, this study suggests that routinely collected clinical data may be useful for daily prediction of FN and that further development of such screening tools could potentially support personalized infection prevention. Infections can be a life-threatening complication of chemotherapy in patients with acute myeloid leukemia. Here, we developed a screening tool to help physicians detect these infections early. Using registry data from two Finnish university hospital districts, we trained an AI model to predict early infection onset over the next 48 hours. The model required seven variables, including routine laboratory tests, temperature measurements, time since each chemotherapy cycle started, and information on the treatment phase and antibiotic use. Such a screening tool could potentially support more personalized supportive care. However, the results must be confirmed prospectively before clinical adoption.
Excess fat mass is causally linked to multiple diseases, but the use of existing therapies, such as glucagon-like peptide-1 receptor agonists, is limited by varying effects and common side effects, including loss of fat-free mass. We aimed to identify proteins associated with fat mass, but ideally not also associated with fat-free mass, as potential drug targets for alternative therapeutic strategies. We used UK Biobank data on plasma levels of 3K proteins (n = 35K) and fat and fat-free mass (n = 368K). We applied a machine learning procedure to select proteins for downstream cis Mendelian randomisation analyses, which estimated associations of genetically predicted protein levels with fat mass. These were followed by colocalisation analyses to assess shared causal genetic variants and further cis Mendelian randomisation analyses to assess associations with fat-free mass. Here we present evidence on the associations of genetically predicted levels of 21 proteins with fat mass, including five which also colocalise with the trait (AGER, CRIM1, DNER, NEFL, and PRRT3). Seven of the 21 proteins have no clear association with fat-free mass, and ADM has an association with fat-free mass opposite in direction to its association with fat mass, suggesting that modulating these proteins may be less likely to also lower fat-free mass. Two proteins, AGER and ADM, have been investigated in advanced-stage clinical trials for indications unrelated to adiposity. These findings support prioritising several proteins for further research as potential drug targets for fat mass reduction. They highlight proteins that may help diversify therapy options beyond glucagon-like peptide-1 receptor agonists and suggest possible repurposing opportunities. High levels of body fat can increase risk of several diseases, but existing treatments do not work equally well for everyone and can have side effects. Some treatments may reduce fat-free mass, which includes muscle and other non-fat tissue. We aimed to identify proteins that may be useful targets for alternative therapeutic strategies to reduce fat mass. We used data from UK Biobank, including on blood protein levels, body composition measures, and genetic information. We found evidence linking 21 proteins with fat mass, some of which also appeared not to have a relation with fat-free mass. These findings highlight proteins to prioritise in further studies as possible treatment targets, which may ultimately help develop more options for people who could benefit from reducing body fat, ideally without also reducing fat-free mass. Orešković et al. use UK Biobank proteomic and body composition data, applying machine learning, cis Mendelian randomisation, and colocalisation to prioritise targets for lowering fat mass without lowering fat-free mass. MR analyses yield 21 proteins related to fat mass, five of which also colocalised with the trait; seven proteins had no, and one had an opposite-direction association with fat-free mass.
Abstract Background: Despite established consensus about the individuality of brain physiology and structural changes, current neuroimaging biomarker paradigms heavily rely on population averages. Here, we define normativity not as a single reference point but as a landscape of permissible configurations arising from diverse physiological manifestations. Methods: We introduce the Nearest Neighbor Normativity (N 3 ) framework, designed to parse the natural heterogeneity in brain structural measurements into a diversity-aware biomarker of brain structural decline. Through repeated comparisons within different demographic subgroups, N 3 contextualizes an individual’s measurements from several viewpoints along the aging continuum. Relying on local density estimation, it accommodates multiple, shared normative configurations within and across age groups. We use T1-weighted MRI data from 29,883 individuals for training and 7,013 individuals for validation, and benchmark our framework against Brain Age models and Normative Modeling. We evaluate each biomarker’s ability to detect neurodegenerative diseases, using them as representative models of atypical brain structural decline. Results: In group-level analyses, the N 3 biomarker shows the largest effect sizes in the detection of Mild Cognitive Impairment, Alzheimer’s Disease, and Frontotemporal Dementia. Similarly, the N 3 biomarker achieves the highest predictive performance in the classification of neurodegenerative diseases on a single subject level. Notably, the N 3 estimates remain stable across age and robust to compositional changes in the reference sample. Finally, correlation analyses indicate that it captures distinct and complementary aspects of brain structural variation compared to existing approaches. Conclusions: Our findings underscore that rethinking normativity assessments to explicitly accommodate natural inter-individual variability can advance our collective efforts toward truly personalized patient care.
Metabolic dysfunction is influenced by various factors including environmental effects and genetic variants, and recent evidence reveals close associations between metabolic dysfunction and neurodevelopmental or neuropsychiatric disorders. However, the mechanistic link between them remains unclear. To clarify these relationships, we utilized mice with haploinsufficiency in the autism spectrum disorder-related gene lysine methyltransferase 2c (Kmt2c) (Kmt2c+/fs mice), in which we previously confirmed significantly less body weight. We characterized body composition, small intestinal transcriptome, fecal metagenome, plasma metabolome, and hepatic mitochondrial morphology and biochemical activity in male Kmt2c+/fs mice and wild-type controls. Hepatic transcriptomic changes and lipid accumulation were also assessed. Group comparisons were performed using two-sided Mann-Whitney U-tests, two-way repeated measures ANOVA, and enrichment analyses with appropriate multiple-testing correction. Here we show that Kmt2c+/fs mice have decreased body mass index and body fat mass. The small intestine and fecal metagenome show minimal alterations, while plasma metabolomic analysis reveals an increase of metabolites related to glucose and amino acid metabolism. Hepatic mitochondria display altered morphology and biochemical activity. The liver of Kmt2c+/fs mice exhibits decreased lipid accumulation and the downregulation of genes related to lipid metabolism, particularly fatty acid synthesis. These findings indicate that KMT2C deficiency triggers functional defects in lipid metabolism in the liver, accompanied by upregulation of glucose and amino acid metabolism and consequently less body weight. The mechanism of metabolic dysfunction observed in neurodevelopmental and neuropsychiatric disorders largely remains unclear. Lysine methyltransferase 2c (Kmt2c) is one of autism spectrum disorder (ASD)-related genes, and Kmt2c mutant mice exhibit ASD-like phenotypes and less body weight. We precisely analyzed metabolic profiles of Kmt2c+/fs mice, and discovered lower body mass index and decreased fat mass. While these phenotypes were unlikely to be explained by changes in the intestine or gut bacteria, we found changes in morphology and biochemical activity of hepatic mitochondria. The liver of Kmt2c+/fs mice showed decreased lipid accumulation and downregulation of lipid metabolism-related genes. These results provide insight into the onset mechanism of metabolic dysfunction in neurodevelopmental and neuropsychiatric disorders, especially associated with epigenetic regulations.